Omniab, INC

OmniAb Inc. announced robust second quarter 2026 financial results, showcasing a substantial increase in revenue and an improved full-year financial outlook driven by strong business momentum and partner program progress.

OmniAb, Inc. announces the appointment of Amechi Nwachuku as Chief Operating Officer, effective July 13, 2026, with a compensation package including salary, bonus, and stock options.

OmniAb, Inc. held its 2026 Annual Meeting of Shareholders on June 17, 2026, where shareholders elected two Class I directors and ratified the appointment of Ernst & Young LLP as the independent auditor.

OmniAb Inc. announced strong first-quarter 2026 financial results, driven by milestone revenue, and raised its full-year revenue and cash guidance.

OmniAb, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting decreased revenue but an expanded partner base and new technology launch.

OmniAb, Inc. has adopted amended and restated bylaws, enhancing corporate governance by aligning with universal proxy rules and increasing disclosure requirements for shareholder proposals.

OmniAb, Inc. announced its second quarter 2026 financial results, showcasing a substantial increase in total revenue driven by license and milestone payments, while continuing to report net losses and a decrease in cash reserves.

OmniAb, Inc. announced its first quarter 2026 financial results, showcasing a significant 247% increase in total revenue driven by a substantial rise in license and milestone revenue.

OmniAb reported a significant decline in Q3 2025 revenue and an increased net loss, despite a recent $30 million private placement.

OmniAb, Inc. reported a significant net loss for Q2 2025, driven by substantial declines in license, milestone, service, and royalty revenues, despite reduced operating expenses.

OmniAb, Inc. reports its financial results for the first quarter ended March 31, 2025, showing a slight revenue increase and a reduced net loss compared to the same period in 2024.

OmniAb's third quarter 2024 results show a decrease in revenue compared to the same period last year, primarily due to lower milestone and service revenue.

OmniAb, Inc. reported a 29% decrease in total revenue and an increased net loss for fiscal year 2025, despite growth in active partnerships and the launch of new antibody discovery technologies.

OmniAb's 2024 10-K filing reveals a decrease in revenue but growth in active partnerships and programs, alongside ongoing investments in its technology platform.

OmniAb, Inc. reported its full year 2023 results, showcasing growth in partnerships and programs, while also detailing strategic investments in technology and infrastructure.

Amechi Ekeke Nwachuku, Chief Operating Officer of OmniAb, Inc., received 800,000 shares of common stock on August 1, 2026.

OmniAb, Inc. Director Carolyn R. Bertozzi reported transactions involving common stock, restricted stock units, and stock options on June 17, 2026.

OmniAb, Inc. Director Jennifer R. Cochran acquired 20,000 shares through RSU vesting and was granted 40,000 stock options.

OmniAb, Inc. Director Steven C. Crouse reported transactions involving common stock, restricted stock units, and stock options.

OmniAb, Inc. Director Philip J. Gotwals reported transactions involving common stock, restricted stock units, and stock options on June 17, 2026.

OmniAb, Inc. Director John L. Higgins reported transactions involving the acquisition of 20,000 Restricted Stock Units and 40,000 Stock Options.

OmniAb, Inc. announces its annual shareholder meeting to be held on June 17, 2025, with proxy materials accessible online.

OmniAb, Inc. has scheduled its 2025 Annual Meeting of Shareholders for June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

OmniAb, Inc. will hold its annual shareholder meeting on June 18, 2024, to vote on the election of directors and the ratification of Ernst & Young LLP as the company's independent registered accounting firm.

OmniAb, Inc. has scheduled its 2024 Annual Meeting of Shareholders for June 18, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Whitefort Capital Management, LP, along with its Co-Managing Partners David Salanic and Joseph Kaplan, now beneficially own 7.1% of OmniAb, Inc. common stock.

Robert Goldstein and affiliated entities report an aggregate beneficial ownership of 8.5% in OmniAb, Inc. common stock as of December 31, 2025.

Whitefort Capital Management, LP, along with its Co-Managing Partners David Salanic and Joseph Kaplan, reported a 9.9% beneficial ownership stake in OmniAb, Inc. as of September 30, 2025.

Ash X LP, RLG GP LLC, RLG Capco II LLC, Robert Goldstein, and Joel Greenblatt have disclosed significant beneficial ownership in OmniAb, Inc.

Whitefort Capital Management, LP and its Co-Managing Partners, David Salanic and Joseph Kaplan, have disclosed a passive 8.4% beneficial ownership stake in OmniAb, Inc.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 0.8% beneficial ownership stake in OmniAb, Inc. as of June 30, 2025.